XOMA Royalty completes $4.29 per share acquisition of Generation Bio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/19/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Medifast launches Trilivy, replacing its Optavia brand
- Adobe has received a takeover approach by a Big Tech company - Betaville
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
February 9, 2026 9:53 AM ESTGeneration Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value Right
EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (XOMA Royalty or the Company), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company successfully completed its previously announced tender offer to acquire all outstanding shares of Generation Bio Co. (NASDAQ: GBIO) (Generation Bio) common stock for a price per share of $4.2913 in cash (the Cash Amount), plus one non-tradeable contingent... More
